News Sentiment

SYRE sentiment intelligence

Spyre Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed

Weighted score 53 Balanced news tone 59 relevant articles

Exchange NASDAQ United States

Sector Healthcare Market context

Industry Biotechnology Read-through group

Latest close 97.74 Week of 10 Jul 2026

Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+12.8% over one week, +21.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Spyre Therapeutics stock hits 52-week high at 102.46 USD

Market Reaction

Price moving ahead of tone

62/100 confidence

Primary event Market update 81/100 classification

One-week reaction 12.8% Price confirming higher

Trend fit Trend active 21.0% over four weeks

Fair value 237.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance

Positive 12

Neutral 38

Negative 9

Relevance

Why the article matched

Direct first

Direct company coverage 51

Industry context 8

Sector context 0

Sources

Coverage mix

Publishers

Stock Titan 13

Market source 10

TradingView 6

Investing.com 4

MT Newswires 3

Quiver Quantitative 2

Moomoo 2

Quartr 2

Event Lens

What the news is about

Classified themes

Market update 34

Earnings 16

Analyst action 4

Guidance 2

Deals and strategy 2

Balance sheet 1

Sentiment Trail

Score over time

50 baseline

Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59

TradingView Direct company coverage

Enterprise value to EBIT forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE

The article discusses the enterprise value to EBIT forward of Spyre Therapeutics, Inc. (NASDAQ: SYRE). It provides a brief overview of the company's financial data as listed on the Nasdaq Stock Market. The content is presented from TradingView, focusing on financial metrics for t

Tone: Neutral 50/100
Event: Market update
Published: 27 Jun 2026 05:39
Source: TradingView

Stock Titan Direct company coverage

Spyre Therapeutics (NASDAQ: SYRE) launches $500M at‑the‑market program

Tone: Neutral 50/100
Event: Market update
Published: 26 Jun 2026 07:00
Source: Stock Titan

Stock Titan Direct company coverage

SYRE (NASDAQ): Affiliate files Form 144 to sell 15,000 shares on 06/25/2026

Tone: Negative 34/100
Event: Market update
Published: 25 Jun 2026 07:00
Source: Stock Titan

MT Newswires Direct company coverage

Spyre Therapeutics Shares Fall After Director Sells $2 Million in Stock

Tone: Negative 30/100
Event: Market update
Published: 24 Jun 2026 18:40
Source: MT Newswires

MT Newswires Direct company coverage

Spyre Therapeutics Insider Sold Shares Worth $2,000,000, According to a Recent SEC Filing

Tone: Neutral 50/100
Event: Market update
Published: 24 Jun 2026 07:39
Source: MT Newswires

Market source Direct company coverage

Spyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE)

Tone: Neutral 50/100
Event: Market update
Published: 24 Jun 2026 07:00
Source: Market source

Seeking Alpha Direct company coverage

Spyre stock falls after $2M insider sale (SYRE:NASDAQ)

Tone: Negative 22/100
Event: Market update
Published: 24 Jun 2026 07:00
Source: Seeking Alpha

MT Newswires Direct company coverage

Deutsche Bank Adjusts Spyre Therapeutics Price Target to $135 From $115, Maintains Buy Rating

Tone: Positive 58/100
Event: Analyst action
Published: 23 Jun 2026 11:27
Source: MT Newswires

Stock Titan Direct company coverage

Spyre (SYRE) fund converts Series B preferred, then exits common stake

Tone: Neutral 50/100
Event: Deals and strategy
Published: 23 Jun 2026 07:00
Source: Stock Titan

Stock Titan Direct company coverage

Director at Spyre Therapeutics (SYRE) sells 20,000 shares under 10b5-1 plan

Tone: Neutral 50/100
Event: Market update
Published: 23 Jun 2026 07:00
Source: Stock Titan

Stock Titan Direct company coverage

Spyre Therapeutics (SYRE) CMO sells 8,333 shares, retains 313,334 options

Tone: Neutral 50/100
Event: Market update
Published: 03 Jun 2026 07:00
Source: Stock Titan

Stock Titan Direct company coverage

Spyre finishes arthritis trial enrollment, targets 2026 results in three diseases

Tone: Neutral 50/100
Event: Earnings
Published: 03 Jun 2026 07:00
Source: Stock Titan

simplywall.st Industry context

There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings

Tone: Negative 34/100
Event: Earnings
Published: 15 May 2026 07:00
Source: simplywall.st

Market source Industry context

Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings

Tone: Neutral 50/100
Event: Earnings
Published: 14 May 2026 07:00
Source: Market source

simplywall.st Industry context

Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results

Tone: Positive 66/100
Event: Earnings
Published: 11 May 2026 07:00
Source: simplywall.st

Market source Industry context

Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00

Tone: Neutral 50/100
Event: Earnings
Published: 11 May 2026 07:00
Source: Market source

Market source Direct company coverage

Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?

Tone: Neutral 50/100
Event: Market update
Published: 30 Apr 2026 07:00
Source: Market source

Market source Direct company coverage

Spyre Therapeutics (SYRE): Favorite Stock of Elite Money Managers

Tone: Neutral 50/100
Event: Market update
Published: 27 Apr 2026 07:00
Source: Market source

Market source Industry context

Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks

Tone: Neutral 50/100
Event: Earnings
Published: 25 Apr 2026 07:00
Source: Market source

Market source Direct company coverage

Here’s What Raymond James Says About Spyre Therapeutics Inc (SYRE)

Tone: Neutral 50/100
Event: Market update
Published: 23 Apr 2026 07:00
Source: Market source

Stock Titan Direct company coverage

Perceptive (NASDAQ: SYRE) reports 4.32M shares, 5.0% stake

Tone: Neutral 50/100
Event: Deals and strategy
Published: 22 Apr 2026 07:00
Source: Stock Titan

Market source Industry context

Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)

Tone: Neutral 50/100
Event: Earnings
Published: 21 Apr 2026 07:00
Source: Market source

Market source Direct company coverage

Spyre (SYRE) Climbs 42% as Treatment Candidate Poses ‘Best-in-Class’ Potential

Tone: Neutral 50/100
Event: Market update
Published: 19 Apr 2026 07:00
Source: Market source

Stock Titan Direct company coverage

Spyre pulls in $463.5M after underwriters take all extra shares

Tone: Neutral 50/100
Event: Market update
Published: 16 Apr 2026 07:00
Source: Stock Titan

Quiver Quantitative Direct company coverage

Spyre Therapeutics Announces $403 Million Public Offering of Common Stock

Tone: Neutral 50/100
Event: Market update
Published: 15 Apr 2026 07:00
Source: Quiver Quantitative

Stock Titan Direct company coverage

Spyre moves to raise $300M, with room to expand the sale to $345M

Tone: Positive 66/100
Event: Market update
Published: 13 Apr 2026 07:00
Source: Stock Titan

TradingView Industry context

A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack

Tone: Neutral 50/100
Event: Earnings
Published: 29 Mar 2026 07:00
Source: TradingView

PR Newswire Direct company coverage

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Tone: Neutral 50/100
Event: Earnings
Published: 08 May 2025 07:00
Source: PR Newswire

PR Newswire Direct company coverage

Spyre Therapeutics Announces $180 Million Private Placement

Tone: Neutral 50/100
Event: Market update
Published: 18 Mar 2024 07:00
Source: PR Newswire